Stockreport

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

Oculis Holding AG  (OCS) 
PDF Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis ( [Read more]